FIELD: pharmaceutics.
SUBSTANCE: present invention describes a non-aqueous gel composition useful for administering pharmaceutically active agents, particularly for transtympanic administration of pharmaceutically active agents. Non-aqueous gel composition contains castor oil in amount of 85 to 95 wt.%, based on the total weight of the composition, oleoylmacrogolglyceride, preferably Labrafil®, present in amount of 2 to 6 wt.%, based on the total weight of the composition, at least one thickener, preferably silicon dioxide, more preferably, colloidal silicon dioxide, present in amount of 1 to 6 wt.%, based on the total weight of the composition, and wherein the viscosity of the composition at temperature of 25 °C is from 1,400 to 2,400 mPa·s, preferably from 1,400 to 1,800 mPa·s.
EFFECT: disclosed is a non-aqueous gel composition.
11 cl, 11 dwg, 11 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOUNDS USED AS POTASSIUM CHANNEL OPENERS | 2018 |
|
RU2779131C2 |
| NEW COMPOUNDS USED AS POTASSIUM CHANNEL OPENERS | 2018 |
|
RU2779111C2 |
| APOPTOSIS INDUCING AGENTS FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2011 |
|
RU2568611C2 |
| DISPERSIBLE PREPARATION OF ANTIINFLAMMATION AGENT | 2004 |
|
RU2319508C2 |
| AMINOBORNANE DERIVATIVE AND METHOD OF ITS OBTAINING, AS WELL AS ITS USE | 2019 |
|
RU2809188C2 |
| 2-OXA-5-AZABICYCLO[2.2.1]HEPTANE-3-YL DERIVATIVES | 2015 |
|
RU2697651C2 |
| 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | 2020 |
|
RU2796605C2 |
| CATHEPSIN CYSTEINE PROTEASE INHIBITORS | 2014 |
|
RU2692799C2 |
| AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | 2012 |
|
RU2615995C2 |
| METHOD OF INHIBITION, TABLET AND CAPSULE | 1996 |
|
RU2109510C1 |
